FERRING-PHARMACEUTICALS
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005907/en/
Evotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones.
“To achieve leadership in reproductive medicine and women’s health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics,” said Per Falk, Chief Science Officer, Ferring Pharmaceuticals. “Evotec is a highly regarded company in this field, and this alliance offers the prospect of significant innovation for patients. Together, we have the potential to make a difference for both men and women who are struggling to start a family, and for women suffering from gynaecological conditions.”
“The integration of our industry-leading small molecule discovery and development platform with Ferring’s expertise in reproductive medicine and women’s health will create a powerful combination that we hope will create a difference for patients suffering from fertility and gynaecological conditions. We very much look forward to working with such an innovative partner, ” commented Dr Mario Polywka, Chief Operating Officer of Evotec.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a
research-driven, specialty biopharmaceutical group committed to helping
people around the world build families and live better lives.
Headquartered in Saint-Prex, Switzerland, Ferring is a leader in
reproductive medicine and women’s health, and in specialty areas within
gastroenterology and urology. Ferring has been developing treatments for
mothers and babies for over 50 years. Today, over one third of the
company’s research and development investment goes towards finding
innovative and personalised healthcare solutions to help mothers and
babies, from conception to birth. Founded in 1950, Ferring now employs
approximately 6,500 people worldwide, has its own operating subsidiaries
in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com , or connect with us on Twitter , Facebook , Instagram , LinkedIn and YouTube .
About Evotec AG
Evotec is a drug discovery alliance and
development partnership company focused on rapidly progressing
innovative product approaches with leading pharmaceutical and
biotechnology companies, academics, patient advocacy groups and venture
capitalists. We operate worldwide and our more than 2,400 employees
provide the highest quality stand-alone and integrated drug discovery
and development solutions. We cover all activities from target-to-clinic
to meet the industry’s need for innovation and efficiency in drug
discovery and development (EVT Execute). The Company has established a
unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial
experience and expertise in key therapeutic areas including neuronal
diseases, diabetes and complications of diabetes, pain and inflammation,
oncology, infectious diseases, respiratory diseases and fibrosis. On
this basis, Evotec has built a broad and deep pipeline of approx. 100
co-owned product opportunities at clinical, pre-clinical and discovery
stages (EVT Innovate). Evotec has established multiple long-term
alliances with partners including Bayer, Boehringer Ingelheim, Celgene,
CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG .
Forward looking statements
Information set forth in this
press release contains forward-looking statements, which involve a
number of risks and uncertainties. The forward-looking statements
contained herein represent the judgement of Evotec as of the date of
this press release. Such forward-looking statements are neither promises
nor guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond our control, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005907/en/
Contact:
Ferring Pharmaceuticals Bhavin Vaid Head of Corporate Communications +41 58 301 0952 (direct) +41 79 191 0632 (mobile) bhavin.vaid@ferring.com or Lindsey Rodger Senior Manager, Corporate Communications +41 58 451 4023 (direct) +41 79 191 0486 (mobile) lindsey.rodger@ferring.com or Gabriele Hansen VP Corporate Communications & Investor Relations T. +49 (0)40 560 81 255 F. +49 (0)40 560 81 333 gabriele.hansen@evotec.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom